El interés en corto de Fidelity Disruptive Finance ETF da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Fidelity Disruptive Finance ETF. Los datos de interés en corto se actualizan cada dos semanas.

Fidelity Disruptive Finance ETF (NASDAQ:FDFF), Informe de interés en corto

Financial Services

Technology

Industrials

Other

Real Estate

The fund investing at least 80 percent of assets in securities of disruptive finance companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. This may include creating, providing, or contributing to new or expanded business models, value networks, pricing, and delivery of products and services.

Blackrock Inc

Brp Group Inc Class A

Mastercard Inc Class A

Capital One Financial Corp

Short Terms

Adyen Nv

Finecobank Spa

Fidelity Disruptive Finance ETF

The special dividend will be payable no later than January 31, 2025, or earlier, if the proposed merger with Blue Owl Capital closes before that date.&nbsp;

News

Dividends

OBDC

OBDE

Blue Owl Capital Corporation III Declares Special Dividend Of $0.52 Per Share

Management

Ryder System Announced Cristina Gallo-Aquino as CFO, effective January 1, 2025

Offerings

NAAS

NaaS Technology Inc Files For Offering Up To 4.8M American Depositary Shares

Buybacks

EBAY

On December 12, 2024, eBay Board Authorizes Incremental $3B Under Stock Repurchase Program, In Addition To Remaining Amounts Previously Authorized - Filing

BD (Becton, Dickinson and Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), a leading global medical technology company, today issued the following statement:
BD has reached an agreement with the U.S. Securities and Exchange Commission (SEC) to resolve the previously disclosed investigation related to prior public disclosures and SEC reporting regarding the BD Alaris&#x2122; System, which was acquired by BD from CareFusion in 2015 and is part of the BD Medication Management Solutions business.
The SEC Order, the findings of which BD neither admits nor denies, relate to matters concerning BD Alaris that occurred more than four years ago. As part of the settlement, BD has agreed to pay $175 million to the SEC, an amount that was reserved and disclosed in the company's fiscal year 2024 Form 10-K and was contemplated in BD's fiscal year 2025 cash flow plan. No financial restatements are required as a result of the settlement, and the settlement amount does not impact BD's investments in innovation or its previously disclosed capital allocation strategy. BD is not updating its fiscal 2025 guidance as a result of the settlement. The company believes that settling with the SEC is the right course of action to fully resolve this matter and move forward.
The BD Alaris&#x2122; System is safe and effective and is a critical part of health care in the United States. The system has been used for many years to safely deliver IV therapies to patients, including throughout the COVID-19 pandemic. The updated BD Alaris&#x2122; System received 510(k) clearance from the U.S. Food and Drug Administration in July 2023, and the company continues to update its Alaris fleet.
BD has implemented a number of improvements to its operational and governance processes and related disclosure practices. BD is committed to operating with integrity and the highest ethical standards to produce high-quality, safe and effective products and serve as a trusted partner for its customers and their patients.

Legal

BD Resolves Previously Disclosed SEC Investigation Related To Prior Public Disclosures And SEC Reporting Regarding The BD Alaris System; BD Has Agreed To Pay $175M To The SEC; BD Is Not Updating Its Fiscal 2025 Guidance As A Result Of The Settlement

The earnings results for Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) for Q4 were made public on Monday, December 16, 2024 at 04:35 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Compass Minerals Intl missed estimated earnings by -71.0%, reporting an EPS of $-0.77 versus an estimate of $-0.45.
Revenue was down $24.80 million from the same period last year.
<h3>Overview of Past Earnings</h3>
The company missed on EPS by $0.27 in the previous quarter, leading to a 3.0% drop share price change the next day.
Here's a look at Compass Minerals Intl's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.74</td>
<td>0.27</td>
<td>0.26</td>
<td>-0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.01</td>
<td>1.49</td>
<td>0.05</td>
<td>-0.06</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>197.77M</td>
<td>406.92M</td>
<td>357.90M</td>
<td>231.26M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>202.90M</td>
<td>364.00M</td>
<td>341.70M</td>
<td>233.60M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Compass Minerals Intl <a href="https://www.benzinga.com/quote/CMP/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Compass Minerals Intl: Q4 Earnings Insights

Due to the continued unpredictability of timing related to the closing of new contracts, the Company has not provided more specific guidance related to the timing of bookings.

Guidance

STRM

Streamline Health Reiterates $15.5M Implemented SaaS ARR Adjusted EBITDA Breakeven Run Rate Expectation; Accelerates Expectation For Achievement The Goal To H1 Of FY25

Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) reported quarterly losses of $(0.77) per share which missed the analyst consensus estimate of $(0.45) by 71.11 percent. This is a 1183.33 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $208.80 million which missed the analyst consensus estimate of $209.00 million by 0.10 percent. This is a 10.62 percent decrease over sales of $233.60 million the same period last year.

Earnings Misses

Compass Minerals Intl Q4 Adj $(0.77) Misses $(0.45) Estimate, Sales $208.80M Miss $209.00M Estimate

Ryder System Announced The Appointment Of John J. Diez To President And COO, Effective January 1, 2025

Streamline Health Q3 EPS $(0.61) Up From $(3.15) YoY, Sales $4.42M Down From $6.13M YoY

CENT

Central Garden & Pet Increases Authorization Under Stock Repurchase Program; To Purchase Up To An Additional $100M Of Issued And Outstanding Shares

Fiscal Year 2025 Guidance
Amentum affirms its fiscal year 2025 guidance originally presented at Capital Markets Day on August 13, 2024 and provides Adjusted Diluted Earnings Per Share (EPS) guidance.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(in millions, except per share data)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="7" rowspan="1">Fiscal Year 2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$13,800</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$14,200</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,060</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,100</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Diluted EPS1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.00</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.20</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$475</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$525</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="9" rowspan="1">1 – Represents a Non-GAAP financial measure - see the related explanations included elsewhere in this release. Amentum does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures due to the inherent difficulty in forecasting and quantifying certain significant items. These items are uncertain, depend on various factors and could have a material impact on GAAP reported results for the relevant period.</td>
</tr>
</tbody>
</table>
</figure>

AMTM

Amentum Holdings Sees FY25 EPS $2.00-$2.20; Revenue $13.8B-$14.2B

Biotech

Events

General

TNYA

Tenaya Therapeutics To Announce Initial Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 Gene Therapy For MYBPC3-Associated Hypertrophic Cardiomyopathy On Dec. 17, 2024

Amentum Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.26 by 7.69 percent. The company reported $2.21 billion in sales this quarter. This is a 3.51 percent increase over sales of $2.14 billion the same period last year.

Earnings Beats

Amentum Holdings Q3 EPS $0.28 Beats $0.26 Estimate, Sales $2.21B Up From $2.14B YoY

Phase 3 KEYFORM-008 trial evaluated the fixed-dose combination of favezelimab and pembrolizumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL) whose disease has progressed following prior anti-PD-1 therapy.&nbsp;
Patients currently in this trial may continue on therapy until study completion. KEYFORM-008 is the only Phase 3 study in the KEYFORM clinical development program for which results are not available.&nbsp;
The company has made this decision after a thorough evaluation of data from the favezelimab clinical program and will prioritize the development of other candidates in its comprehensive and diversified oncology pipeline. This decision is not based on any concerns about the safety of this fixed-dose combination.

Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial

Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (KEYTRUDA) in the KeyVibe program. Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program.
&nbsp;
&nbsp;

Merck Reports Discontinuation Of Clinical Development Programs For Vibostolimab, An Anti-TIGIT Antibody, And Favezelimab, An Anti-LAG-3 Antibody

WIIM

RCAT

Red Cat Holdings shares are trading lower after the company reported worse-than-expected Q2 financial results.

RICK

Rick Hospitality shares are trading higher after the company reported better-than-expected Q4 financial results.

BNIX

Bannix Acquisition Extends Initial Business Combination From Dec. 14 2024 To Jan. 14, 2025.

In times of geopolitical uncertainty, investors often turn to stable assets like Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) <a href="https://www.benzinga.com/partner/commodities/24/12/42459580/some-anticipate-a-bear-market-in-2025-but-geopolitical-conflicts-may-continue-to-drive-gold-p">to protect their wealth.</a>
Just recently, AFP <a href="https://www.yahoo.com/news/under-fire-scholz-trigger-german-135928390.html?fr=sycsrp_catchall">reported </a>that German Chancellor Olaf Scholz lost a confidence vote, essentially marking the conclusion of his embattled administration. This political upheaval, coupled with the <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42465746/french-government-collapse-challenges-macrons-grip-on-power">French government&#8217;s collapse</a> earlier this month, has set the stage for safe-haven speculation.
Billed as the world&#8217;s leading gold company, NEM stock represents a proxy for the precious metal. Historically, investors have viewed gold as the ultimate form <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41390144/gold-could-reach-3-000-by-2025-bank-of-america-analyst-says-ultimate-perceived-safe">of wealth preservation.</a>
Another fundamental catalyst for higher precious metal prices is inflation. Analysts widely expect the Federal Reserve to announce a 25-basis-point <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42514008/fed-poised-to-cut-interest-rates-by-0-25-this-week-heres-why-your-focus-should-shift-to-other-signals">rate cut</a> on Wednesday. Naturally, this anticipated action has reignited inflation concerns, which, all other things being equal, should be positive for gold.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="1022" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16145826/NEM-stock-12162024.jpg" alt="" class="wp-image-694602" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16145826/NEM-stock-12162024.jpg 1022w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16145826/NEM-stock-12162024-300x173.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16145826/NEM-stock-12162024-768x444.jpg 768w" sizes="(max-width: 1022px) 100vw, 1022px" /></figure>
Finally, NEM stock appears to be sitting on a psychologically significant technical support line at $40 per share. While the security has been volatile since late October, the negative velocity has slowed in recent sessions. Therefore, intrepid investors may look to NEM as a bounce-back candidate.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42514008/fed-poised-to-cut-interest-rates-by-0-25-this-week-heres-why-your-focus-should-shift-to-other-signals">Fed Poised To Cut Interest Rates By 0.25% This Week: Here&#8217;s Why Your Focus Should Shift To Other Signals</a>
<h2 class="wp-block-heading">Laying the Framework of the Bull Call Spread</h2>
Of course, the easiest mechanism to speculate on Newmont stock is to buy the company's shares in the open market. However, this approach lacks leverage. Currently, the gold producer carries a market capitalization of nearly $46 billion. Simply put, there's likely not going to be much movement in its share price.
Subsequently, many retail traders turn to buying call options. According to data from the New York Stock Exchange, these market participants <a href="https://www.nyse.com/data-insights/trends-in-options-trading#:~:text=As%20Chart%201%20below%20shows,%2C%20reaching%2045%25%20in%20July.">tend to buy low-priced options</a>; that is, far out-the-money derivatives that have little chance of being net profitable.
A better approach may be to deploy the <a href="https://www.benzinga.com/money/bull-spread">bull call spread</a>. Here, a trader buys a call for a particular options chain. However, the distinction between a straight call purchase and a bull call spread is that the trader simultaneously sells a call at a higher strike price (for the same expiration date).
To be fair, the structure of the trade caps the maximum reward (or payout) at the point represented by the higher short call strike. However, the benefit is twofold. First, the trader's net bullish position is discounted because the gross credit received from the short call helps partially offset the debit paid for the long call. Second, the threshold to profitability (i.e. the breakeven point) is effectively lowered by the aforementioned credit.
Therefore, the bull call spread allows traders to consider more probabilistically favorable transactions rather than taking longshot odds (such as "cheap" far OTM options).
<h2 class="wp-block-heading">Calculating an Ideal Spread for NEM Stock</h2>
With a popular security like Newmont stock, there are several bull call spreads to choose from. Ideally, though, the name of the game is to target spreads that are likely to be successful while also providing adequate payouts.
To better understand the market's anticipated move, traders can deploy a stochastic analysis to calculate the projected share price movement. This process involves multiplying the stock price with its option chain's implied volatility (IV) and time decay adjustment (or the square root of the calendar days to expiration divided by 365 days).
For example, the Dec. 27 options chain expires in 11 calendar days and features an <a href="https://optioncharts.io/options/NEM/volatility-skew?option_type=all&amp;expiration_dates=2024-12-27:w&amp;strike_range=all">average IV</a> of 28.75%. Assuming a share price of $40.05, the product of the three metrics comes out to just under $2. In other words, the market anticipates, at most, NEM stock to rise to $42.05 or, at worst, fall to $38.05 by Dec. 27.
A compelling idea within this options chain may be to consider the 39/41 bull call spread (buy the $39 call, sell the $41 call). At time of writing, the net debit paid comes out to $110 (which is also the most that can be lost in the trade). Should the trade be fully successful — which would involve NEM stock reaching $41 or higher — the reward would be $90 or a nearly 82% payout.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/12/42513807/trump-says-softbanks-100b-commitment-to-us-is-monumental-demonstration-of-confidence-in-americas-future">Trump Says SoftBank&#8217;s $100B Commitment To US Is &#8216;Monumental Demonstration Of Confidence In America&#8217;s Future&#8217;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Eurozone

Commodities

Options

Options Corner: German Crisis Opens Safe-Haven Play In Newmont Call Options

Fidelity Disruptive Finance ETF declares quarterly distribution of $0.1530

Fidelity Disruptive Finance ETF declares $0.05 dividend

FDFF

Comments

Fidelity Disruptive Finance ETF

Interés en corto

Fidelity Disruptive Finance ETF (NASDAQ:FDFF), Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL